Citius Oncology shares surge 33.58% after-hours on strong early LYMPHIR adoption, payer coverage, and expanding clinical development.

Citius Oncology surged 33.58% in after-hours trading following a series of commercial updates highlighting strong early adoption of its newly launched therapy LYMPHIR for the treatment of cutaneous T-cell lymphoma. The company reported sequential order growth, with 83% of target institutions progressing LYMPHIR through formulary review, and secured reimbursement access for approximately 80% of covered lives. Positive clinical data from investigator-led studies, including a trial in combination with pembrolizumab and another prior to CAR-T therapy, further reinforced LYMPHIR’s potential in broader oncology settings. These developments, combined with expanding market access, international distribution agreements, and a growing commercial infrastructure, signaled strong momentum for the product and fueled investor optimism.